249 related articles for article (PubMed ID: 9734399)
1. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.
Lefebvre AM; Chen I; Desreumaux P; Najib J; Fruchart JC; Geboes K; Briggs M; Heyman R; Auwerx J
Nat Med; 1998 Sep; 4(9):1053-7. PubMed ID: 9734399
[TBL] [Abstract][Full Text] [Related]
2. Activators of the nuclear receptor PPARgamma enhance colon polyp formation.
Saez E; Tontonoz P; Nelson MC; Alvarez JG; Ming UT; Baird SM; Thomazy VA; Evans RM
Nat Med; 1998 Sep; 4(9):1058-61. PubMed ID: 9734400
[TBL] [Abstract][Full Text] [Related]
3. Differentiation and reversal of malignant changes in colon cancer through PPARgamma.
Sarraf P; Mueller E; Jones D; King FJ; DeAngelo DJ; Partridge JB; Holden SA; Chen LB; Singer S; Fletcher C; Spiegelman BM
Nat Med; 1998 Sep; 4(9):1046-52. PubMed ID: 9734398
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
5. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells.
Ikawa H; Kameda H; Kamitani H; Baek SJ; Nixon JB; Hsi LC; Eling TE
Exp Cell Res; 2001 Jul; 267(1):73-80. PubMed ID: 11412039
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Grau R; Iñiguez MA; Fresno M
Cancer Res; 2004 Aug; 64(15):5162-71. PubMed ID: 15289320
[TBL] [Abstract][Full Text] [Related]
7. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Staels B; Koenig W; Habib A; Merval R; Lebret M; Torra IP; Delerive P; Fadel A; Chinetti G; Fruchart JC; Najib J; Maclouf J; Tedgui A
Nature; 1998 Jun; 393(6687):790-3. PubMed ID: 9655393
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells.
Shao J; Sheng H; DuBois RN
Cancer Res; 2002 Jun; 62(11):3282-8. PubMed ID: 12036946
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
Araki Y; Okamura S; Hussain SP; Nagashima M; He P; Shiseki M; Miura K; Harris CC
Cancer Res; 2003 Feb; 63(3):728-34. PubMed ID: 12566320
[TBL] [Abstract][Full Text] [Related]
10. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
Han S; Inoue H; Flowers LC; Sidell N
Clin Cancer Res; 2003 Oct; 9(12):4627-35. PubMed ID: 14555539
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Osawa E; Nakajima A; Wada K; Ishimine S; Fujisawa N; Kawamori T; Matsuhashi N; Kadowaki T; Ochiai M; Sekihara H; Nakagama H
Gastroenterology; 2003 Feb; 124(2):361-7. PubMed ID: 12557142
[TBL] [Abstract][Full Text] [Related]
12. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
Pancione M; Forte N; Sabatino L; Tomaselli E; Parente D; Febbraro A; Colantuoni V
Hum Pathol; 2009 May; 40(5):714-25. PubMed ID: 19121846
[TBL] [Abstract][Full Text] [Related]
13. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
Calviello G; Di Nicuolo F; Gragnoli S; Piccioni E; Serini S; Maggiano N; Tringali G; Navarra P; Ranelletti FO; Palozza P
Carcinogenesis; 2004 Dec; 25(12):2303-10. PubMed ID: 15358633
[TBL] [Abstract][Full Text] [Related]
14. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
15. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells.
Xu Y; Iyengar S; Roberts RL; Shappell SB; Peehl DM
J Cell Physiol; 2003 Jul; 196(1):131-43. PubMed ID: 12767049
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Badawi AF; Badr MZ
Int J Oncol; 2002 Jun; 20(6):1109-22. PubMed ID: 12011987
[TBL] [Abstract][Full Text] [Related]
17. Differential formation of beta-catenin/lymphoid enhancer factor-1 DNA binding complex induced by nitric oxide in mouse colonic epithelial cells differing in adenomatous polyposis coli (Apc) genotype.
Mei JM; Hord NG; Winterstein DF; Donald SP; Phang JM
Cancer Res; 2000 Jul; 60(13):3379-83. PubMed ID: 10910042
[TBL] [Abstract][Full Text] [Related]
18. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.
Crawford HC; Fingleton BM; Rudolph-Owen LA; Goss KJ; Rubinfeld B; Polakis P; Matrisian LM
Oncogene; 1999 May; 18(18):2883-91. PubMed ID: 10362259
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer.
Dimberg J; Hugander A; Sirsjö A; Söderkvist P
Anticancer Res; 2001; 21(2A):911-5. PubMed ID: 11396184
[TBL] [Abstract][Full Text] [Related]
20. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
Easwaran V; Lee SH; Inge L; Guo L; Goldbeck C; Garrett E; Wiesmann M; Garcia PD; Fuller JH; Chan V; Randazzo F; Gundel R; Warren RS; Escobedo J; Aukerman SL; Taylor RN; Fantl WJ
Cancer Res; 2003 Jun; 63(12):3145-53. PubMed ID: 12810642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
